These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 32394515)

  • 1. Vogt-Koyanagi-Harada-like syndrome induced by immune checkpoint inhibitors in a patient with melanoma.
    Yoshida S; Shiraishi K; Mito T; Sayama K
    Clin Exp Dermatol; 2020 Oct; 45(7):908-911. PubMed ID: 32394515
    [No Abstract]   [Full Text] [Related]  

  • 2. Vogt-Koyanagi-Harada-like syndrome in the setting of combined anti-PD1/anti-CTLA4 therapy.
    Godse R; Mcgettigan S; Schuchter LM; Ellebrecht CT; Chu EY
    Clin Exp Dermatol; 2021 Aug; 46(6):1111-1112. PubMed ID: 33846999
    [No Abstract]   [Full Text] [Related]  

  • 3. Concurrent Vogt-Koyanagi-Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma.
    Gambichler T; Seifert C; Lehmann M; Lukas C; Scheel C; Susok L
    Immunotherapy; 2020 May; 12(7):439-444. PubMed ID: 32308086
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of Ipilimumab-Induced Vogt-Koyanagi-Harada Syndrome With Oral Dexamethasone.
    Witmer MT
    Ophthalmic Surg Lasers Imaging Retina; 2017 Nov; 48(11):928-931. PubMed ID: 29121363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case Report: Ipilimumab-induced Multisystem Autoimmune-like Toxicities Suggestive of Vogt-Koyanagi-Harada-like Syndrome.
    Monferrer-Adsuara C; Hernández-Bel L; Hernández-Garfella ML; Remolí-Sargues L; Ortiz-Salvador M; Castro-Navarro V; Cervera-Taulet E
    Optom Vis Sci; 2021 Nov; 98(11):1309-1316. PubMed ID: 34510146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vogt-Koyanagi-Harada Syndrome Induced by Pembrolizumab in a Patient with Non-Small Cell Lung Cancer.
    Tamura T; Akimoto E; Matsumoto C; Mori S; Nishi T; Kudo K; Kuyama S
    J Thorac Oncol; 2018 Oct; 13(10):1606-1607. PubMed ID: 29730378
    [No Abstract]   [Full Text] [Related]  

  • 7. Development of Vogt-Koyanagi-Harada disease-like uveitis during treatment by anti-programmed death-1 antibody: a case report.
    Wang JN; Zhang Y; Huang CY; Li K; Yu XB
    BMC Ophthalmol; 2024 Jun; 24(1):240. PubMed ID: 38849786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of Schönlein-Henoch purpura induced by immune checkpoint inhibitor in a patient with metastatic melanoma.
    Belkaid S; Berger M; Nouvier M; Picard C; Dalle S
    Eur J Cancer; 2020 Nov; 139():169-172. PubMed ID: 32992155
    [No Abstract]   [Full Text] [Related]  

  • 9. Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors.
    Rapisuwon S; Izar B; Batenchuk C; Avila A; Mei S; Sorger P; Parks JM; Cooper SJ; Wagner D; Zeck JC; Charabaty AJ; Atkins MB
    J Immunother Cancer; 2019 Mar; 7(1):61. PubMed ID: 30832716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient.
    Arai T; Harada K; Usui Y; Irisawa R; Tsuboi R
    J Dermatol; 2017 Aug; 44(8):975-976. PubMed ID: 27649838
    [No Abstract]   [Full Text] [Related]  

  • 11. Vogt-Koyanagi-Harada disease-like uveitis induced by vemurafenib for metastatic cutaneous malignant melanoma.
    Fusumae T; Kamiya K; Maekawa T; Komine M; Murata S; Inoda S; Takahashi R; Kawashima H; Ohtsuki M
    J Dermatol; 2018 Jun; 45(6):e159-e160. PubMed ID: 29314171
    [No Abstract]   [Full Text] [Related]  

  • 12. Vitiligo-like lesions developing upon immune checkpoint inhibition in advanced melanoma.
    Grän F; Emmerich K; Mohme S; Goebeler M; Gesierich A
    Eur J Dermatol; 2020 Feb; 30(1):72-73. PubMed ID: 32250264
    [No Abstract]   [Full Text] [Related]  

  • 13. Checkpoint Inhibitor-Associated Vogt-Koyanagi-Harada Disease Presenting 3 Months Following Discontinuation of Nivolumab.
    Tieger MG; Eliott D; Cakir B; Dahrouj M
    Ophthalmic Surg Lasers Imaging Retina; 2023 Mar; 54(3):183-187. PubMed ID: 36944065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Vogt-Koyanagi-Harada-like uveitis under immune checkpoint inhibitor treatment for metastasized malignant melanoma].
    Mihailovic N; Dyballa J; Herz S; Fluck M; Alnawaiseh M; Merté RL; Eter N
    Ophthalmologe; 2020 May; 117(5):467-471. PubMed ID: 31489479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal triamcinolone acetonide in Vogt-Koyanagi-Harada syndrome.
    Karacorlu M; Arf Karacorlu S; Ozdemir H
    Eur J Ophthalmol; 2006; 16(3):481-3. PubMed ID: 16761256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VOGT-KOYANAGI-HARADA DISEASE-LIKE UVEITIS IN A PATIENT WITH ADVANCED MELANOMA TREATED BY SEQUENTIAL ADMINISTRATION OF NIVOLUMAB AND DABRAFENIB/TRAMETINIB THERAPY.
    Madoe A; Schauwvlieghe PP; Jacob J
    Retin Cases Brief Rep; 2023 Sep; 17(5):611-615. PubMed ID: 37643052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors.
    Rahma OE; Reuss JE; Giobbie-Hurder A; Shoja E Razavi G; Abu-Shawer O; Mehra P; Gupta S; Simon R; Khleif SN
    Clin Cancer Res; 2021 Jan; 27(2):485-491. PubMed ID: 33082209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Impaired Spermatogenesis With the Use of Immune Checkpoint Inhibitors in Patients With Metastatic Melanoma.
    Scovell JM; Benz K; Samarska I; Kohn TP; Hooper JE; Matoso A; Herati AS
    JAMA Oncol; 2020 Aug; 6(8):1297-1299. PubMed ID: 32556068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review.
    Dupré A; Michot JM; Schoeffler A; Frumholtz L; Baroudjian B; Delyon J; Lebbe C; Lambotte O
    Br J Haematol; 2020 Jun; 189(5):985-992. PubMed ID: 32243578
    [No Abstract]   [Full Text] [Related]  

  • 20. Occurrences and Outcomes of Immune Checkpoint Inhibitors-Induced Vitiligo in Cancer Patients: A Retrospective Cohort Study.
    Babai S; Voisin AL; Bertin C; Gouverneur A; Le-Louet H
    Drug Saf; 2020 Feb; 43(2):111-117. PubMed ID: 31630381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.